Zhirui (Jerry) Lian is a research advisor at Eli Lilly and Company where he is responsible for structural characterization of biotherapeutics (monoclonal antibody, bispecific monoclonal antibody, peptides, nucleotides and emerging cell and gene therapy products) using mass spectrometry and other techniques and also serves as lead of a cross-functional CMC project team. He earned his PhD in Biochemistry at Boston University.